Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO1 | P15559 | 6/20 | 0.76 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | MGAM | O43451 | 6/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.45 |
| ▸ | PCSK7 | Q16549 | 1/20 | 0.45 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14170077 | 0.84 | NQO1 (0.78) | NQO1MAOAMGAMMAOBCYP2C9 | |
| SCHEMBL3364138 | 0.79 | NQO1 (0.71) | NQO1MAOAMGAMMAOBMEN1 | |
| SCHEMBL8934476 | 0.79 | NQO1 (0.61) | NQO1MAOAMGAMCYP2C9MEN1 | |
| SCHEMBL14169888 | 0.77 | MGAM (0.65) | NQO1MAOAMGAMMAOBCYP2C9 | |
| SCHEMBL3912373 | 0.75 | NQO1 (0.65) | NQO1MAOAMGAMMAOBALDH1A1 | |
| SCHEMBL29953437 | 0.73 | NQO1 (0.61) | NQO1MAOAMGAMMAOBMEN1 | |
| SCHEMBL11568363 | 0.73 | NQO1 (0.61) | NQO1MAOAMGAMMAOBMEN1 | |
| SCHEMBL14170081 | 0.72 | MGAM (0.64) | NQO1MAOAMGAMMAOBCYP2C9 | |
| SCHEMBL14170121 | 0.72 | MGAM (0.63) | NQO1MAOAMGAMMAOB | |
| SCHEMBL14169987 | 0.71 | MGAM (0.55) | NQO1MAOAMGAMMAOBCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1575589-B1 | ATROPISOMERS OF 3-SUBSTITUTED-4-ARYLQUINOLIN-2-ONE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2010-06-30 | — | — | EP | disclosed |
| EP-1575589-A4 | ATROPISOMERS OF 3-SUBSTITUTED-4-ARYLQUINOLIN-2-ONE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2008-05-21 | — | — | EP | disclosed |
| EP-1133474-B1 | 3-SUBSTITUTED-4-ARYLQUINOLIN-2-ONE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2007-02-21 | — | — | EP | disclosed |
| EP-1575589-A1 | ATROPISOMERS OF 3-SUBSTITUTED-4-ARYLQUINOLIN-2-ONE DERIVATIVES | Bristol-Myers Squibb Company (US) | 2005-09-21 | — | — | EP | disclosed |
| US-6939968-B2 | Atropisomers of 3-substituted-4-arylquinolin-2-one derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-09-06 | — | — | US | disclosed |
| EP-1133474-A4 | 3-SUBSTITUTED-4-ARYLQUINOLIN-2-ONE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2005-02-16 | — | — | EP | disclosed |
| US-20040147749-A1 | Atropisomers of 3-substituted-4-arylquinolin-2-one derivatives | BRISTOL-MYERS SQUIBB COMPANY | 2004-07-29 | — | — | US | disclosed |
| WO-2004058260-A1 | ATROPISOMERS OF 3-SUBSTITUTED-4-ARYLQUINOLIN-2-ONE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-07-15 | — | — | WO | disclosed |
| EP-1233947-A4 | PREPARATION OF 3-SUBSTITUTED-4-ARYLQUINOLIN-2-ONE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2003-01-02 | — | — | EP | disclosed |
| EP-1233947-A1 | PREPARATION OF 3-SUBSTITUTED-4-ARYLQUINOLIN-2-ONE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-08-28 | — | — | EP | disclosed |
| US-6353119-B1 | FROM A SUBSTITUTED COUMARIN AND USING A PHOTOCHEMICAL CYCLIZATION METHOD ON A DIHYDROFURAN INTERMEDIATE | BRISTOL-MYERS SQUIBB COMPANY | 2002-03-05 | — | — | US | disclosed |
| EP-1133474-A1 | 3-SUBSTITUTED-4-ARYLQUINOLIN-2-ONE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-09-19 | — | — | EP | disclosed |
| WO-2001040191-A1 | PREPARATION OF 3-SUBSTITUTED-4-ARYLQUINOLIN-2-ONE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-06-07 | — | — | WO | disclosed |
| US-6184231-B1 | NEUROPROTECTANTS; TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS, TRAUMATIC BRAIN INJURY, SEXUAL DYSFUNCTION | BRISTOL-MYERS SQUIBB | 2001-02-06 | — | — | US | disclosed |
| WO-2000034244-A1 | 3-SUBSTITUTED-4-ARYLQUINOLIN-2-ONE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147749-A1 | Atropisomers of 3-substituted-4-arylquinolin-2-one derivatives | KCNN3, KCNN1, KCNN2 | NQO1 373/4885MAOA 2106/4885MGAM 3792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.